Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious <i>BRCA</i> Mutation
Rachna T. Shroff(University of Arizona), Susan M. Domchek(University City Science Center), Andrew Hendifar(Cedars-Sinai Medical Center), Robert H. Vonderheide(University of Pennsylvania), Ravit Geva(Tel Aviv Sourasky Medical Center), Kevin Lin(The University of Texas MD Anderson Cancer Center), Ron Epelbaum(University of Bern), Andrew V. Biankin(University of Glasgow), Lindsey Rolfe, Robert R. McWilliams(Mayo Clinic in Arizona), Sandra Goble(Clovis Oncology (United States)), Heidi Giordano(Mayo Clinic in Arizona)
Cited by 177
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k